Press Releases

HOUSTON--(BUSINESS WIRE)-- Tellurian Inc. (Tellurian or the Company) (NYSE American: TELL) continued making progress on Driftwood LNG phase one construction with Bechtel.

Executive Chairman Martin Houston said, “Over the past few months, our senior team has sharpened its focus on stability, financial discipline and execution, and we are laser-focused on bringing Driftwood to final investment decision. To this end, we continue to take important steps to improve... (continue reading...)

Blue Arc™ Expects to Deliver New Units Beginning Late 2024

NOVI, Mich., May 2, 2024 /PRNewswire/ -- The Shyft Group, Inc. (NASDAQ: SHYF), the North American leader in specialty vehicle manufacturing, assembly, and upfit for the commercial, retail, and specialty vehicle markets today announced a purchase order with FedEx for an initial order of 150 Blue Arc™ EV Trucks to be integrated into the FedEx pickup and delivery fleet in the U.S. This order reflects the... (continue reading...)

Early Warning Report Filing - Dr. Strashin Now Holds In-Excess of 16%

Thunder Bay, Ontario--(Newsfile Corp. - May 2, 2024) - Thunder Gold Corp. (TSXV: TGOL) (FSE: Z25) (OTCQB: TGOLF) (formerly White Metal Resources Corp.) ("Thunder Gold" or the "Company") has executed a binding Letter of Intent (the "LOI") to option an 80% interest in the Seagull Lake property (ON) and a Definitive Agreement (the "DA") to option a 100% interest in the Startrek property (NF). ... (continue reading...)

Exploration in Raptor Zone Showing Widespread Channel of Nickel Mineralization

Tamarack, Minnesota--(Newsfile Corp. - May 2, 2024) - Talon Metals Corp. (TSX: TLO) (OTC Pink: TLOFF) ("Talon" or the "Company"), the majority owner and operator of the Tamarack Nickel-Copper-Cobalt Project ("Tamarack Nickel Project") in central Minnesota, is pleased to announce significant progress in its 2024 exploration plan, particularly focusing on an update to the drilling program in the... (continue reading...)

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers

Company expects to enroll first patient in mid-2024

PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”)... (continue reading...)